ReferencePoint

More intelligence behind your care. Less on your shoulders.

ReferencePoint is an AI platform for patients, their families and their doctors. In the patient app, your guide Sam explains each visit in plain words, handles the tasks you approve and passes your questions to your care team. Your doctor gets one report built from your records, scans, check-ins and research, with sources.

Request early access hello@referencepoint.ai

Behind the phone, her records, imaging, check-ins, Apple Health data and research flow from her side into her doctor’s report.

The summary of her October 7 visit with its next steps. She hands the ride to her November 3 labs and MRI to Sam; Sam shows the call before making it, she approves, and the ride is booked. Her check-in: the front camera watches her copy each face move from a drawing and relax between them, she taps green circles as soon as they appear and leaves the gray squares alone, taps steadily through a timed task, and tells Sam her ride for the MRI is set and her bag is by the door; it is saved for her care team. She asks whether her urea could cost less; Sam shows the call to the pharmacy, she approves, the price comes back and the coverage question goes to her care team. She asks to move her Thanksgiving-week infusion, and Sam sends that to her care team, who decide.

Enlarging treated left occipital metastasis

Yolanda Griffin · Nov 12 follow-up · Records to Oct 31

Biopsy/LITT reconsideration for an enlarging irradiated occipital lesion; the November perfusion MRI remains pending.

  1. The fourth bevacizumab dose would postpone the biopsy/LITT washout again.

    Dose 3 is planned for 11/05 and dose 4 for 11/25, neither yet documented as given. Dr. Vale’s 4-6-week interval reaches 12/03-12/17 after a last dose on 11/05, but 12/23-01/06/2027 after 11/25. She asks to move dose 4 for Thanksgiving in Chicago. These dates are waiting intervals, not clearance; the next infusion decision also affects a recurrent-tumor trial’s washout.1, 2, 4, 5Dose 3 is planned for 11/05 and dose 4 for 11/25. Dr. Vale’s 4-6-week interval reaches 12/03-12/17 after 11/05, but 12/23-01/06 after 11/25; these are waiting intervals, not clearance.2, 4

    Sources 3 records, 1 trial entry2 records

  2. Symptom improvement has not established that the occipital lesion is necrosis alone.

  3. She has conflicting sodium instructions, with urea stopped and salt continued at home.

  4. She still has right-sided visual reserve that matters to her independence.

  5. Her steroid taper has not established adrenal recovery before possible anesthesia.

  6. Recruiting TrialsHer procedure choice and bevacizumab timing affect recurrent-tumor trial access.

Be among the first to use ReferencePoint.

We are preparing a small first group of patients, families and clinicians, alongside a clinical research study. Leave your email and we will be in touch as places open.

Requesting early access does not enroll you in research. Investors and partners are welcome to write to hello@referencepoint.ai.

Which describes you?

Please leave medical details out; this form is not monitored for medical needs.

Privacy